Status | Study |
Recruiting |
Study Name: Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Condition: Neurofibromatosis 1 Plexiform Neurofibromas Date: 2015-09-05 |
Recruiting |
Study Name: Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Condition: Neurofibromatosis Type 1 Plexiform Neurofibromas Date: 2015-06-12 Interventions: Other: Acceptance and Commitment Therapy (ACT) Acceptance and Commitment Therapy (ACT), a newer generati |
Recruiting |
Study Name: Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery Condition: Neurofibromatosis Type 1 Plexiform Neurofibroma Date: 2015-04-02 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Condition: Neurofibroma, Plexiform Precursor Cell Lymphoblastic Leukemia-L Date: 2015-03-17 Interventions: Drug: PLX3397 Take oral drug daily for a 28 day cycle |
Recruiting |
Study Name: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas Condition: Plexiform Neurofibromas Date: 2014-06-25 Interventions: Drug: Imatinib Mesylate oral administration Other Na |
Recruiting |
Study Name: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Condition: Cancer Date: 2014-04-24 Interventions: Drug: Trametinib Trametinib is |
Active, not recruiting |
Study Name: Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +) Condition: NF1 Neurofibromatosis Plexiform Neur Date: 2014-03-14 Interventions: Drug: Cabozantinib Open label Phase II clinical trials. All subjects will start cabozantinib at 40 mg. S |
Completed |
Study Name: Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condition: Neurofibromatosis Date: 2012-08-22 Interventions: Drug: Gleevec Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects |
Completed |
Study Name: Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Condition: Neurofibromatosis Type 1 Plexiform Neurofibroma Date: 2011-08-08 Interventions: Drug: RAD001: Everolimus 10 mg of RAD001 will be self-administered orally once daily continuously for on |
Suspended |
Study Name: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Condition: Neurofibromatosis NF1 Plexiform Neur Date: 2011-07-25 Interventions: Drug: Sutent®/Sunitinib Upon enrollment, subjects will receive Sutent® orally. Adults (Age > |